Vertex puts a blockbuster valuation on its CRISPR deal

The third iteration of Vertex and Crispr’s collaboration over CTX001, a gene-editing therapy for rare blood clotting disorders, shows how hopes for the project have ballooned. Vertex is paying $900m up front, plus a potential $200m milestone on first approval, to up its share of profits and costs from 50% to 60%.